TF
FHTX icon

TIAA FSB’s Foghorn Therapeutics FHTX Stock Holding History

TIAA FSB’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,469
Closed -$89.7K – 580
2023
Q1 		$89.7K Hold
14,469
– – ﹤0.01% 561
2022
Q4 		$92.3K Hold
14,469
– – ﹤0.01% 557
2022
Q3 		$124K Hold
14,469
– – ﹤0.01% 555
2022
Q2 		$197K Buy
+14,469
New +$187K ﹤0.01% 569

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA FSB's FHTX Position: Q2 2023 in Review

TIAA FSB sold out of Foghorn Therapeutics (FHTX) in Q2 2023, closing a stake of 14,469 shares — an estimated $89.7K sold.

TIAA FSB first reported a position in FHTX in Q2 2022 and held it in 4 quarters. The position peaked at $197K in Q2 2022. 59 funds tracked by Wall St. Rank hold FHTX as of Q2 2023.

  • TIAA FSB reported no remaining Foghorn Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TIAA FSB sold 14,469 Foghorn Therapeutics shares in Q2 2023, an estimated $89.7K.
  • TIAA FSB first reported a position in Foghorn Therapeutics in Q2 2022 and held it in 4 quarters.
  • TIAA FSB's Foghorn Therapeutics position peaked at $197K in Q2 2022.
  • 59 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2023.

Based on TIAA FSB's 13F filing for Q2 2023, filed 31 Jul 2023.